{'fraction_non_alphanumeric': 0.022033898305084745, 'fraction_numerical': 0.020338983050847456, 'mean_word_length': 4.91, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abbott agrees to implement a compassionate use program for Ritonavir.


 In early 1996, Abbott Pharmaceutical plans to establish a global compassionate use program for Ritonavir (ABT-538), its candidate protease inhibitor for the treatment of HIV/AIDS. Fifteen hundred people with advanced AIDS will be enrolled in the program, limited to patients with CD4+ counts of fifty or less who are failing other available antiretroviral drugs, and who have not enrolled in any other protease inhibitor trials. A formal announcement on the details of the program is expected in early November 1995.
